David T. Hagerty
2018
In 2018, David T. Hagerty earned a total compensation of $849.1K as Executive Vice President, Clinical Development at Conatus Pharmaceuticals, a 3% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $137,735 |
|---|---|
| Option Awards | $281,606 |
| Salary | $414,864 |
| Other | $14,846 |
| Total | $849,051 |
Hagerty received $414.9K in salary, accounting for 49% of the total pay in 2018.
Hagerty also received $137.7K in non-equity incentive plan, $281.6K in option awards and $14.8K in other compensation.
Rankings
In 2018, David T. Hagerty's compensation ranked 9,939th out of 14,244 executives tracked by ExecPay. In other words, Hagerty earned more than 30.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,939 out of 14,244 | 30th |
Division Manufacturing | 4,017 out of 5,765 | 30th |
Major group Chemicals And Allied Products | 1,512 out of 2,128 | 29th |
Industry group Drugs | 1,276 out of 1,817 | 30th |
Industry Pharmaceutical Preparations | 981 out of 1,391 | 30th |
Source: SEC filing on April 30, 2019.
Hagerty's colleagues
We found two more compensation records of executives who worked with David T. Hagerty at Conatus Pharmaceuticals in 2018.